global-women-health-orthopedics-congress-2018-posters

Page 44

S e p t e m b e r 0 6 - 0 7 , 2 0 1 8 | B a n g k o k , T h a i l a n d

allied

academies

Joint Event on

Global Women Health 2018 & Orthopedics Congress 2018

Archives of General Internal Medicine

ISSN: 2591-7951

Volume 2

BREAST CANCER, GYNECOLOGY AND WOMEN HEALTH

ORTHOPEDICS AND RHEUMATOLOGY

World Congress on

Annual Conference on

Arch Gen Intern Med 2018, Volume 2 | DOI: 10.4066/2591-7951-C3-009

HORMONE THERAPY IN UROGYNECOLOGY

A Ramsey

Chicago Incontinence Center, USA

rogenital embryonic development is so close that the genital and lower urinary systems are hormonally dependent. Aging

and hormonal deficiency will affect both parts equally, and disease and physiological as well as pathological disorders are

hormonally influenced. Screening, investigating, and management of urogynecology/lower urinary tract disorders must take the

hormonal influence in consideration as neither set of systems can be viewed in isolation. Many medical professionals make the

mistake of only thinking of estrogen when talking about hormonal influences and therapy. Several hormones affect both urological

and genital systems equally. The hormones include estrogen, progesterone, testosterone, DHEA, cortisol, thyroid, pregnenolone,

and melatonin. These hormones and their influences on the urogenital systems will be discussed. Clear evidence exists to support

that recurrent urinary tract infection, urinary frequency, urinary incontinence, urgency, nocturia, as well as dysuria may influence

hormonal imbalance as a precursor to these symptoms. This presentation will explore the causative relationship and the value of

this enormous therapeutic benefit in the field of urogynaecology, both in relation of dysfunctions of the lower urinary tract, and in

the female genital organ prolapse.